Clemastine

Synonyms: 富马酸氯马斯汀; HS-592; Meclastine
Clemastine (HS-592; Meclastine) 是一种口服有效且可穿透血脑屏障的 H1 组胺受体 (H1 histamine receptor) 拮抗剂,具有强大的抗过敏作用,同时还可拮抗毒蕈碱型乙酰胆碱受体 (mAChR),尤其是 M1 和 M4 亚型,并具有多种超越抗组胺作用的药理活性,特别是在促进中枢神经系统髓鞘再生、激活自噬 (autophagy) 和焦亡 (Pyroptosis)、抗凋亡 (apoptosis) 和神经保护以及抗炎等方面。
产品编号: MS-W21417 纯度: 99.26% CAS No.: 15686-51-8 分子式: C21H26ClNO 分子量: 343.89
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Clemastine (HS-592; Meclastine) 是一种口服有效且可穿透血脑屏障的 H1 组胺受体 (H1 histamine receptor) 拮抗剂,具有强大的抗过敏作用,同时还可拮抗毒蕈碱型乙酰胆碱受体 (mAChR),尤其是 M1 和 M4 亚型,并具有多种超越抗组胺作用的药理活性,特别是在促进中枢神经系统髓鞘再生、激活自噬 (autophagy) 和焦亡 (Pyroptosis)、抗凋亡 (apoptosis) 和神经保护以及抗炎等方面。

生物实验数据

生物活性 Clemastine (HS-592; Meclastine) is an orally active, blood-brain barrier-penetrant H1 histamine receptor antagonist with potent anti-allergic effects that also antagonizes muscarinic acetylcholine receptors (mAChR), particularly the M1 and M4 subtypes, and exhibits multiple pharmacological activities beyond antihistamine action, especially in promoting central nervous system remyelination, activating autophagy and pyroptosis, and exerting anti-apoptotic, neuroprotective, and anti-inflammatory effects.
IC50 & Target

H1 Receptor

 

体外研究
(In Vitro)

Clemastine (10 μM; 12 h) 可促进 Nrf2 核转位,激活 Nrf2/SQSTM1 通路,并在经 Hb 处理的 HT-22 细胞中上调自噬相关基因的转录。
Clemastine (10-50 μM; 1 h) 可直接结合 M4 受体,且 M4 受体信号传导介导了 HT-22 细胞中由 clemastine 诱导的 Nrf2/SQSTM1/TBK1 自噬通路激活。
Clemastine (10 μg/mL; 3-18 h) 可增强经 LPS 预处理的 THP-1 细胞中 ATP 诱导的炎症小体激活以及 GSDMD 依赖性的焦亡。
Clemastine (10 μg/mL; 3-18 h) 可通过 P2RX7 依赖的机制增强 LPS 预刺激的原代人单核细胞来源巨噬细胞中 ATP 诱导的炎症小体活化和焦亡。
Clemastine (10 μg/mL; 18 h) 与 2 mM ATP 联合作用时,可在经 LPS 预处理的人诱导多能干细胞 (iPSC) 来源少突胶质细胞中诱导溶解性细胞死亡。
Clemastine 可通过阻断 CHRM1 并激活 ERK 通路,促进少突胶质前体细胞分化为成熟的髓鞘形成少突胶质细胞。
Clemastine 可通过改变少突胶质前体细胞的膜特性,诱导其进入富含 NMDA 受体的状态。
Clemastine (1.25 μg/mL) 可降低 LPS 刺激的 H9c2 心肌细胞的细胞凋亡水平、改善线粒体结构损伤并促进自噬。

体内研究
(In Vivo)

Clemastine (1 mg/kg;腹腔注射;单次给药) 可改善蛛网膜下腔出血 (SAH) 模型小鼠的短期神经功能,减轻氧化应激与神经元死亡,并激活 Nrf2/SQSTM1 介导的自噬,且这些效应依赖于 Nrf2 和 mTOR 信号通路。
Clemastine (10 mg/kg;口服;每日一次;连续 28 天) 可逆转蛛网膜下腔出血 (SAH) 模型小鼠的长期认知障碍并减轻其海马神经元损伤。
Clemastine 可增强髓鞘再生与髓鞘形成、延缓或减少轴突丢失、促进少突胶质前体细胞及少突胶质细胞分化、保留髓鞘完整性,并在铜宗诱导、炎症性脱髓鞘相关多发性硬化症模型、社会隔离模型、脊髓损伤及脊髓挫伤损伤模型、佩利措伊斯‑梅茨巴赫病模型、溶血卵磷脂诱导脱髓鞘模型中分别逆转行为学改变、改善功能与运动功能恢复,且无免疫系统抑制作用。
Clemastine (10-50 mg/kg; 腹腔注射; 单次给药) 提高 CLP 诱导的脓毒症大鼠的 7 天存活率并降低血清 cTnI 水平;而 30 mg/kg Clemastine 还可改善心脏功能、减轻心肌细胞凋亡与线粒体损伤并促进自噬,其抗凋亡作用依赖于自噬激活。
Clemastine (10 mg/kg; 口服; 每日一次共 21 天) 可促进少突胶质前体细胞分化和髓鞘再生,从而在青光眼小鼠模型中改善视神经和视网膜的结构恢复与功能结局。

Animal Model: C57BL/6 (male, 8 weeks old, subarachnoid haemorrhage model via stereotactic injection of autologous blood)
Dosage: 1 mg/kg
Administration: i.p.; single dose
Result: Improved modified Garcia scale scores relative to SAH + vehicle controls.
Reduced beam balance test hind limb slippage frequency relative to SAH + vehicle controls.
Reduced number of DHE-positive superoxide-producing neurons relative to SAH + vehicle controls.
Reduced number of FJC-positive degenerating neurons relative to SAH + vehicle controls.
Increased Nrf2 protein expression and nuclear translocation, increased LC3-II/LC3-I ratio, and increased autophagosome formation relative to SAH + vehicle controls.
Abolished protective effects on modified Garcia and beam balance scores, as well as changes in Nrf2, Keap1, p-SQSTM1, SQSTM1, and LC3-II/LC3-I levels when co-administered with mTOR activator MHY1485.
Abolished protective effects on modified Garcia and beam balance scores, as well as changes in Nrf2, Keap1, p-SQSTM1, SQSTM1, and LC3-II/LC3-I levels when co-administered with Nrf2 inhibitor ML385.
Animal Model: C57BL/6 (male, 8 weeks old, subarachnoid haemorrhage model via stereotactic injection of autologous blood)
Dosage: 10 mg/kg/day
Administration: p.o.; daily; 28 days
Result: Reduced escape latency in the Morris water maze acquisition phase relative to SAH + vehicle controls.
Increased number of platform site crossings, increased time spent in the platform quadrant, and increased total distance travelled in the platform quadrant in the Morris water maze probe trial relative to SAH + vehicle controls.
Improved recognition index in the novel object recognition test relative to SAH + vehicle controls.
Improved preference index in the Y-maze test relative to SAH + vehicle controls.
Reduced number of FJC-positive degenerating neurons in the hippocampal CA1, CA3, and DG regions relative to SAH + vehicle controls.
Attenuated hippocampal neuronal shrinkage and death relative to SAH + vehicle controls.
Animal Model: Sprague Dawley (adult male, 220-250 g, CLP-induced sepsis)
Dosage: 10 mg/kg; 30 mg/kg; 50 mg/kg
Administration: i.p.; single dose
Result: Significantly reduced serum cardiac troponin I (cTnI) levels and increased 7-day survival rate at 30 mg/kg and 50 mg/kg, with minimal effect at 10 mg/kg.
Significantly increased left ventricular ejection fraction (LVEF) and left ventricular fraction shortening (LVFS), decreased left ventricular end-systolic diameter (LVESD), and attenuated myocardial fiber disorder, edema, red blood cell exudation, and inflammatory cell infiltration at 30 mg/kg.
Reduced the number of TUNEL-positive cardiomyocytes, decreased BAX protein expression, and increased Bcl-2 protein expression at 30 mg/kg.
Improved mitochondrial ultrastructure (reduced swelling, cristae disruption, and vacuolation), increased myocardial ATP content, decreased dynamin-related protein 1 (DRP1) expression, suppressed mitochondrial ROS production, and increased superoxide dismutase 2 (SOD2) expression at 30 mg/kg.
Increased the number of myocardial autophagosomes, elevated the LC3II/LC3I ratio, and increased Beclin 1 protein expression at 30 mg/kg.
Abolished the anti-apoptotic effect (reduced TUNEL-positive cells, reduced BAX, increased Bcl-2) of 30 mg/kg when co-administered with autophagy inhibitor 3-methyladenine.
Animal Model: C57BL/J mice (12 weeks old, 20.0 g; includes NG2-CreERT; Tau-mGFP transgenic mice and littermate controls)
Dosage: 10 mg/kg
Administration: p.o.; daily; day 7 to day 28 post-microbead injection
Result: Increased the number of CC1+ mature oligodendrocytes, Olig2+ total oligodendroglial lineage cells, and reduced the number of Tunel+/Olig2+ apoptotic oligodendroglial cells on day 28 compared to untreated glaucoma mice.
Increased myelinated axon numbers and improved myelin thickness (reduced G-ratio) in optic nerves on day 28 compared to untreated glaucoma mice.
性状 油状物
颜色 Colorless to light yellow

化学信息

分子量 343.89
分子式 C21H26ClNO
CAS No. 15686-51-8
别名 富马酸氯马斯汀; HS-592; Meclastine

储存&溶解度

储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (290.79 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.9079 mL14.5395 mL29.0791 mL72.6977 mL
5 mM0.5816 mL2.9079 mL5.8158 mL14.5395 mL
10 mM0.2908 mL1.4540 mL2.9079 mL7.2698 mL
15 mM0.1939 mL0.9693 mL1.9386 mL4.8465 mL
20 mM0.1454 mL0.7270 mL1.4540 mL3.6349 mL
25 mM0.1163 mL0.5816 mL1.1632 mL2.9079 mL
30 mM0.0969 mL0.4847 mL0.9693 mL2.4233 mL
40 mM0.0727 mL0.3635 mL0.7270 mL1.8174 mL
50 mM0.0582 mL0.2908 mL0.5816 mL1.4540 mL
60 mM0.0485 mL0.2423 mL0.4847 mL1.2116 mL
80 mM0.0363 mL0.1817 mL0.3635 mL0.9087 mL
100 mM0.0291 mL0.1454 mL0.2908 mL0.7270 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础